Manganese-induced reactive oxygen species activate IκB kinase to upregulate YY1 and impair glutamate transporter EAAT2 function in human astrocytes in vitro.


Journal

Neurotoxicology
ISSN: 1872-9711
Titre abrégé: Neurotoxicology
Pays: Netherlands
ID NLM: 7905589

Informations de publication

Date de publication:
09 2021
Historique:
received: 07 06 2021
revised: 14 07 2021
accepted: 21 07 2021
pubmed: 27 7 2021
medline: 5 2 2022
entrez: 26 7 2021
Statut: ppublish

Résumé

Dysregulation of the astrocytic glutamate transporter excitatory amino acid transporter 2 (EAAT2) is associated with several neurological disorders, including Parkinson's disease, Alzheimer's disease, and manganism, the latter induced by chronic exposure to high levels of manganese (Mn). Mechanisms of Mn-induced neurotoxicity include impairment of EAAT2 function secondary to the activation of the transcription factor Yin Yang 1 (YY1) by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). However, the upstream mechanisms by which Mn-induced NF-κB activates YY1 remain to be elucidated. In the present study, we used the H4 human astrocyte cell line to test if Mn activates YY1 through the canonical NF-κB signaling pathway, leading to EAAT2 repression. The results demonstrate that Mn exposure induced phosphorylation of the upstream kinase IκB kinase (IKK-β), leading to NF-κB p65 translocation, increased YY1 promoter activity, mRNA/protein levels, and consequently repressed EAAT2. Results also demonstrated that Mn-induced oxidative stress and subsequent TNF-α production were upstream of IKK-β activation, as antioxidants attenuated Mn-induced TNF-α production and IKK-β activation. Moreover, TNF-α inhibition attenuated the Mn-induced activation of IKK-β and YY1. Taken together, Mn-induced oxidative stress and TNF-α mediates activation of NF-κB signaling and YY1 upregulation, leading to repression of EAAT2. Thus, targeting reactive oxygen species (ROS), TNF-α and IKK-β may attenuate Mn-induced YY1 activation and consequent EAAT2 repression.

Identifiants

pubmed: 34310962
pii: S0161-813X(21)00082-6
doi: 10.1016/j.neuro.2021.07.004
pmc: PMC8440474
mid: NIHMS1730851
pii:
doi:

Substances chimiques

Excitatory Amino Acid Transporter 2 0
Reactive Oxygen Species 0
SLC1A2 protein, human 0
YY1 Transcription Factor 0
YY1 protein, human 0
Manganese 42Z2K6ZL8P
I-kappa B Kinase EC 2.7.11.10

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-103

Subventions

Organisme : NIMHD NIH HHS
ID : U54 MD007582
Pays : United States
Organisme : NCI NIH HHS
ID : SC1 CA200519
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES020852
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES024756
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES031282
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES010563
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

Int J Mol Sci. 2019 Nov 13;20(22):
pubmed: 31766111
Cell Res. 2011 Jan;21(1):103-15
pubmed: 21187859
J Neurosci. 2006 May 10;26(19):5256-64
pubmed: 16687518
EMBO J. 2005 Feb 9;24(3):510-20
pubmed: 15660126
Nat Chem Biol. 2006 May;2(5):249-53
pubmed: 16565714
Food Chem Toxicol. 2019 Mar;125:583-594
pubmed: 30738988
Arch Dermatol Res. 2016 Dec;308(10):733-742
pubmed: 27744496
Exp Ther Med. 2019 Oct;18(4):2859-2866
pubmed: 31572531
Cell Mol Life Sci. 2015 Sep;72(18):3489-506
pubmed: 26033496
J Neurochem. 2010 Mar;112(5):1190-8
pubmed: 20002294
Brain Res Brain Res Rev. 2004 Jul;45(3):250-65
pubmed: 15210307
J Cell Physiol. 2011 Oct;226(10):2484-93
pubmed: 21792905
Nat Immunol. 2008 Dec;9(12):1371-8
pubmed: 18997794
Neurochem Int. 2015 Sep;88:53-9
pubmed: 25128239
FEBS J. 2021 Jan;288(2):640-662
pubmed: 32386462
J Trace Elem Med Biol. 2011 Dec;25(4):191-203
pubmed: 21963226
Mol Cell Biol. 2007 Jun;27(12):4374-87
pubmed: 17438126
Redox Biol. 2021 May;41:101917
pubmed: 33711713
Neurochem Res. 2015 Feb;40(2):402-9
pubmed: 25380696
Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a000158
pubmed: 20300203
Neurosci Lett. 2015 Mar 4;589:73-8
pubmed: 25596441
Neurochem Res. 2014 Jan;39(1):150-60
pubmed: 24277080
Metallomics. 2017 Sep 20;9(9):1251-1259
pubmed: 28661534
Sci Rep. 2014 Oct 28;4:6801
pubmed: 25348053
Biochem Biophys Res Commun. 2013 Sep 6;438(4):628-34
pubmed: 23933318
Toxicol Lett. 2002 Dec 15;136(2):151-8
pubmed: 12425965
Int J Mol Sci. 2021 Apr 28;22(9):
pubmed: 33925013
Mol Neurobiol. 2014 Feb;49(1):380-5
pubmed: 23990375
Clin Pharmacol Ther. 2019 Oct;106(4):884-890
pubmed: 31206613
Int J Mol Sci. 2020 Dec 17;21(24):
pubmed: 33348528
J Neurochem. 2009 Aug;110(3):822-30
pubmed: 19457077
Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H1850-8
pubmed: 19363130
Toxicol Appl Pharmacol. 2009 Oct 15;240(2):219-25
pubmed: 19607852
Oncol Rep. 2017 Jun;37(6):3397-3404
pubmed: 28440462
J Pers Nanomed. 2015;1(1):3-9
pubmed: 26635971
J Biol Chem. 2015 Sep 25;290(39):23725-37
pubmed: 26269591
J Biol Chem. 2013 Oct 4;288(40):28975-86
pubmed: 23955341
Toxicol In Vitro. 2008 Feb;22(1):18-27
pubmed: 17845838
Neuropharmacology. 2019 Dec 15;161:107559
pubmed: 30851309
Neurotoxicology. 2018 Mar;65:280-288
pubmed: 29183790
Cell Signal. 2019 Mar;55:17-25
pubmed: 30543861
Oncogene. 2014 Mar 6;33(10):1297-305
pubmed: 23474754
Drug Des Devel Ther. 2019 Apr 11;13:1155-1162
pubmed: 31043768
Oxid Med Cell Longev. 2015;2015:610813
pubmed: 25834699
J Alzheimers Dis. 2016 Jul 13;53(2):745
pubmed: 27434286
Mol Psychiatry. 2007 Dec;12(12):1065-78
pubmed: 17684493
Future Med Chem. 2012 Sep;4(13):1689-700
pubmed: 22924507
Acta Neurol Belg. 2015 Sep;115(3):221-32
pubmed: 25539775
Can J Physiol Pharmacol. 2018 Dec;96(12):1189-1196
pubmed: 30107137
Mol Cell Biol. 2014 Apr;34(7):1280-9
pubmed: 24469401
Expert Rev Neurother. 2020 Nov;20(11):1109-1121
pubmed: 32799578
Neurobiol Dis. 2015 Dec;84:78-83
pubmed: 25913028
Curr Cancer Drug Targets. 2015;15(2):145-57
pubmed: 25817371
PPAR Res. 2020 Mar 6;2020:2410264
pubmed: 32206061

Auteurs

Asha Rizor (A)

Department of Pharmaceutical Sciences, College of Pharmacy, Florida A&M University, Tallahassee, FL, 32301, USA.

Edward Pajarillo (E)

Department of Pharmaceutical Sciences, College of Pharmacy, Florida A&M University, Tallahassee, FL, 32301, USA.

Ivan Nyarko-Danquah (I)

Department of Pharmaceutical Sciences, College of Pharmacy, Florida A&M University, Tallahassee, FL, 32301, USA.

Alexis Digman (A)

Department of Pharmaceutical Sciences, College of Pharmacy, Florida A&M University, Tallahassee, FL, 32301, USA.

Leyah Mooneyham (L)

Department of Pharmaceutical Sciences, College of Pharmacy, Florida A&M University, Tallahassee, FL, 32301, USA.

Deok-Soo Son (DS)

Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN, USA.

Michael Aschner (M)

Department of Molecular Pharmacology, Albert Einstein College of Medicine Bronx, New York, NY, 10461, USA; Sechenov First Moscow State Medical University, Moscow, Russia.

Eunsook Lee (E)

Department of Pharmaceutical Sciences, College of Pharmacy, Florida A&M University, Tallahassee, FL, 32301, USA. Electronic address: eunsook.lee@famu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH